Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mark Gergen
AddedFeb 17, 2024
UpdatedMay 31, 2026
Mark Gergen

Mark Gergen

Board Member, Poseida Therapeutics

CrunchbaseLinkedInThe Org

Mark Gergen's Career

Poseida Therapeutics
Poseida Therapeutics

San Diego, CA, US

Board Member· Board
Psylin Neurosciences
Psylin Neurosciences

San Diego, CA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mark Gergen's Career

Poseida Therapeutics
Poseida Therapeutics
Public$460.5M3142014San Diego, CA, US
Board Member· Board

Leadership at Poseida Therapeutics

David HirschDavid HirschBoard Member
John SchmidJohn SchmidBoard Member
Cynthia CollinsCynthia CollinsBoard Member
Eric OstertagEric OstertagBoard Member
Mark J GergenMark J GergenCEO
Luke CorningLuke CorningBoard Member

Similar to Poseida Therapeutics

Voyager TherapeuticsVoyager TherapeuticsCambridge, MA, USGene Therapyest. 2014Voyager TherapeuticsCambridge, MA, US · est. 2014

Cambridge-based Voyager Therapeutics, Inc. is a clinical-stage gene therapy company developing treatments for severe CNS diseases.

Public · $374M125
Poseidon InnovationPoseidon InnovationSan Diego, CA, USTherapeuticsPoseidon InnovationSan Diego, CA, US

Poseidon Innovation, a San Diego-based medical organization, expedites drug development for advanced disease treatments.

Series D · $65M5
Kriya TherapeuticsKriya TherapeuticsPalo Alto, CA, USGene Therapiesest. 2019Kriya TherapeuticsPalo Alto, CA, US · est. 2019

Kriya Therapeutics: Pioneering gene therapies for global health challenges in ophthalmology, neurology, and metabolism.

Series C · $600.5M194
Denali TherapeuticsDenali TherapeuticsSan Francisco, CA, USBiotechest. 2015Denali TherapeuticsSan Francisco, CA, US · est. 2015

Denali Therapeutics, a US-based biotech firm, develops medicines for neurodegenerative diseases.

Public · $622M427
Psylin Neurosciences
Psylin Neurosciences
Series A$5M52007San Diego, CA, US
CEO· C-Suite · Management

Leadership at Psylin Neurosciences

Michael R HanleyMichael R HanleyFounder

Similar to Psylin Neurosciences

Psy TherapeuticsPsy TherapeuticsBoston, MA, USDrug Developmentest. 2012Psy TherapeuticsBoston, MA, US · est. 2012

Psy Therapeutics: Innovating novel medicines for CNS disorders like anxiety, depression, and dementia.

Seed · $4M30
NeurolixisNeurolixisSan Diego, CA, USPharmaceuticalsest. 2011NeurolixisSan Diego, CA, US · est. 2011

San Diego-based Neurolixis, a biopharmaceutical firm innovating treatments for central nervous system diseases.

Seed · $15k6
Sensorium TherapeuticsSensorium TherapeuticsBoston, MA, USPsychoactive Medicinesest. 2021Sensorium TherapeuticsBoston, MA, US · est. 2021

Sensorium Therapeutics: Pioneering nature-derived psychoactive medicines through advanced biotechnology.

Series A · $30M22
Lykos TherapeuticsLykos TherapeuticsSan Jose, CA, USPharmaceuticalsest. 2014Lykos TherapeuticsSan Jose, CA, US · est. 2014

Lykos Therapeutics: Revolutionizing mental health with innovative, science-backed psychedelic therapies.

Series A · $100M175

People Similar to Mark Gergen

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoMike VerhielMike VerhielCEO · PsylarisDavid S. BarlowDavid S. BarlowCEO · Psy TherapeuticsMark VarneyMark VarneyCEO · NeurolixisDavid CostelloDavid CostelloCEO · PSITony GiordanoTony GiordanoFounder · TheraVascNithin KrishnaNithin KrishnaCo-Founder · keySkillset